Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 12, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ordinary shares under ShareReward Plan |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.7127 per share |
| Total Volume | 14 Ordinary shares (7 partnership shares + 7 matching shares) |
| Transaction Date | July 11, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a routine executive share acquisition.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a statutory disclosure of an insider transaction.
Key Facts for Investor Verification
- Executive Involved: Ms. E. Walmsley, CEO of GSK Consumer Healthcare.
- Transaction Nature: Initial notification of an acquisition under the Company's ShareReward Plan.
- Share Composition: The 14 shares acquired consist of 7 partnership shares and 7 matching shares.
- Market Price: The transaction occurred at £16.7127 per share on the London Stock Exchange.